Clinical outcome of autologous mononuclear cells transplantation for spinal cord injury: a systematic review and meta-analysis

Hamid Reza Aghayan, Babak Arjmand, Mohsen Yaghoubi, Maziar Moradi-Lakeh, Homa Kashani, Farhad Shokraneh, Hamid Reza Aghayan, Babak Arjmand, Mohsen Yaghoubi, Maziar Moradi-Lakeh, Homa Kashani, Farhad Shokraneh

Abstract

Background: Cell-based therapies can be used to treat neurological diseases and spinal cord injuries. The aim of this study was to assess the clinical outcome of bone marrow derived mononuclear cells (BM-MNCs) transplantation in patients with spinal cord injuries.

Methods: Following a systematic review to detect clinical intervention studies, a meta-analysis was done for pooling data to estimate the outcome of BM-MNCs transplantation. The percentage of the patients with improved ASIA scale from one grade to a higher grade was defined as the main outcome. By considering the study design and outcome measurement, two reviewers independently extracted the data.

Results: Eight relevant primary studies were found; seven qualified studies, with a combined total of 328 patients were assessed by meta-analysis, including 314 ASIA-A, 13 ASIA-B, 94 cervical, 227 thoracic and 60 acute injuries. The percentage of the patients' improvement was tested by meta-analysis through random and fixed models. The overall percentage of all patients' improved ASIA scale after a one- year follow-up (95% CIs) was 43 (0.27-0.59).

Conclusion: Data from published trials revealed that encouraging results were achieved by autologous BMMNCs for the treatment of spinal cord injury. However, the number of clinical trials included in the systematic review was too limited to reach a definite conclusion. More qualified clinical trials with standardized methods are needed to truly justify the outcome of this therapeutic modality in SCI patients.

Keywords: Bone Marrow Derived Mononuclear Cells; Cell Transplantation; Spinal Cord Injury.

Figures

Fig. 1
Fig. 1
Fig. 2
Fig. 2
Fig. 3
Fig. 3
Fig. 4
Fig. 4
Fig. 5
Fig. 5
Fig. 6
Fig. 6
Fig. 7
Fig. 7

References

    1. Tator CH. Update on the pathophysiology and pathology of acute spinal cord injury. Brain Pathol. 1995;5(4):407–13.
    1. Stojkovic M. Stem cells and spinal cord injury. Journal of the Serbian Society for Computational Mechanics. 2011;5(2):17–23.
    1. Vipond N, Zhang J. Stem cell Transplantation for Spinal Cord Injury. Evidence Based Healthcare Advisory Group. 2007:1–21.
    1. Fehlings MG, Vawda R. Cellular Treatments for Spinal Cord Injury: The Time is Right for Clinical Trials. Neurotherapeutics. 2011;8(4):704–20.
    1. Regenberg AC, Hutchinson LA, Schanker B, Mathews DJ. Medicine on the Fringe: Stem Cell-Based Interventions in Advance of Evidence. Stem Cells. 2009;27(9):2312–9.
    1. Moazzami K, Majdzadeh R, Nedjat S. Local intramuscular transplantation of autologous mononuclear cells for critical lower limb ischaemia. Cochrane Database of Systematic Reviews 2011;12:Art. No.: CD008347. DOI:10.1002/14651858.CD008347.pub2.
    1. Cox Jr CS, Baumgartner JE, Harting MT, Worth LL, Walker PA, Shah SK. et al. Autologous bone marrow mononuclear cell therapy for severe traumatic brain injury in children. Neurosurgery. 2011;68(3):588–600.
    1. Phinney DG, Isakova I. Plasticity and therapeutic potential of mesenchymal stem cells in the nervous system. Curr Pharm Des. 2005;11(10):1255–65.
    1. Dasari VR, Spomar DG, Cady C, Gujrati M, Rao JS, Dinh DH. Mesenchymal stem cells from rat bone marrow down regulate Caspase-3 mediated apoptotic pathway after spinal cord injury in rats. Neurochem Res. 2007;32(12):2080–93.
    1. Park HC, Shim YS, Ha Y. et al. Treatment of Complete Spinal Cord Injury Patients by Autologous Bone Marrow Cell Transplantation and Administration of Granulocyte-Macrophage Colony Stimulating Factor. Tissue Eng. 2005;11(5-6):913–22.
    1. Jung JK, Oh CH, Yoon SH, Ha Y, Park S, Choi B. Outcome Evaluation with Signal Activation of Functional MRI in Spinal Cord Injury. J Korean Neurosurg Soc. 2011;50(3):209–15.
    1. Attar A, Ayten M, Ozdemir M. et al. An attempt to treat patients who have injured spinal cords with intralesional implantation of concentrated autologous bone marrow cells. Cytotherapy. 2011;13(1):54–60.
    1. Deda H, Inci MC, Kürekçi AE. et al. Treatment of chronic spinal cord injured patients with autologous bone marrow-derived hematopoietic stem cell transplantation: 1-year follow-up. Cytotherapy. 2008;10(6):565–74.
    1. Geffner LF, Santacruz P, Izurieta M, Flor L. et al. Administration of Autologous Bone Marrow Stem Cells into Spinal Cord Injury Patients via Multiple Routes Is Safe and Improves Their Quality of Life: Comprehensive Case Studies. Cell Transplant. 2008;17(12):1277–93.
    1. Kumar AA, Kumar SR, Narayanan R, Arul K, Baskaran M. Autologous Bone Marrow Derived Mononuclear Cell Therapy for Spinal Cord Injury: A Phase I/II Clinical Safety and Primary Efficacy Data. Exp Clin Transplant. 2009;7(4):241–8.
    1. Syková E, Homola A, Mazanec R. et al. Autologous bone marrow transplantation in patients with subacute and chronic spinal cord injury. Cell Transplant. 2006;15(8-9):675–87.
    1. Yoon SH, Shim YS, Park YH. et al. Complete Spinal Cord Injury Treatment Using Autologous Bone Marrow Cell Transplantation and Bone Marrow Stimulation with Granulocyte Macrophage-Colony Stimulating Factor: Phase I/II Clinical Trial. Stem Cells. 2007;25(8):2066–73.
    1. Tuszynski MH, Steeves JD, Fawcett JW. et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP Panel: clinical trial inclusion/exclusion criteria and ethics. Spinal Cord. 2007;45(3):222–31.
    1. Steeves JD, Lammertse D, Curt A. et al. Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: clinical trial outcome measures. Spinal Cord. 2007;45(3):206–21.
    1. Katalinic OM, Harvey LA, Herbert RD. Effectiveness of stretch for the treatment and prevention of contractures in people with neurological conditions: a systematic review. Phys Ther. 2011;91(1):11–24.
    1. Fawcett JW, Curt A, Steeves JD. et al. Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP Panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord. 2007;45(3):190–205.
    1. Bouhy D, Malgrange B, Multon S. et al. Delayed GM-CSF treatment stimulates axonal regeneration and functional recovery in paraplegic rats via an increased BDNF expression by endogenous macrophages. FASEB J. 2006;20(8):1239–41.
    1. Alvarez-Viejo M, Menendez-Menendez Y, Blanco-Gelaz M, Ferrero-Gutierrez A, Fernandez-Rodriguez M, Gala J, et al., editors. Quantifying Mesenchymal Stem Cells in the Mononuclear Cell Fraction of Bone Marrow Samples Obtained for Cell Therapy. Transplantation proceedings; 2013: Elsevier.
    1. Moore A, McQuay H, Bandolier’s Little Book of Making Sense of the Medical Evidence. Oxford: Oxford University Press, 2006.
    1. Carlos Rodrigues da Silva Filhoa. et al. Assessment of clinical trial quality and its impact on meta-analyses. Rev Saudepublica. 2005;39(6)

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere